209 related articles for article (PubMed ID: 9018092)
1. Clinical evaluation of potential usefulness of CEA, CA 15-3, and MCA in follow-up of breast cancer patients.
Jezersek B; Cervek J; Rudolf Z; Novaković S
Cancer Lett; 1996 Dec; 110(1-2):137-44. PubMed ID: 9018092
[TBL] [Abstract][Full Text] [Related]
2. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
3. Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients.
Pectasides D; Pavlidis N; Gogou L; Antoniou F; Nicolaides C; Tsikalakis D
Am J Clin Oncol; 1996 Oct; 19(5):459-64. PubMed ID: 8823487
[TBL] [Abstract][Full Text] [Related]
4. Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer.
Steger GG; Mader R; Derfler K; Moser K; Dittrich C
Klin Wochenschr; 1989 Aug; 67(16):813-7. PubMed ID: 2796251
[TBL] [Abstract][Full Text] [Related]
5. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
[TBL] [Abstract][Full Text] [Related]
7. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer.
Deprés-Brummer P; Itzhaki M; Bakker PJ; Hoek FJ; Veenhof KH; de Wit R
J Cancer Res Clin Oncol; 1995; 121(7):419-22. PubMed ID: 7635872
[TBL] [Abstract][Full Text] [Related]
8. CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study.
Martoni A; Zamagni C; Bellanova B; Zanichelli L; Vecchi F; Cacciari N; Strocchi E; Pannuti F
Eur J Cancer; 1995 Sep; 31A(10):1615-21. PubMed ID: 7488411
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of mucin-like carcinoma-associated antigen (MCA) in breast cancer.
Rasoul-Rockenschaub S; Zielinski CC; Kubista E; Vavra N; Pospischil E; Staffen A; Czerwenka K; Aiginger P; Spona J
Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1067-72. PubMed ID: 2759162
[TBL] [Abstract][Full Text] [Related]
10. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients.
Lauro S; Trasatti L; Bordin F; Lanzetta G; Bria E; Gelibter A; Reale MG; Vecchione A
Anticancer Res; 1999; 19(4C):3511-5. PubMed ID: 10629644
[TBL] [Abstract][Full Text] [Related]
11. Preliminary study on serum levels of mucinous like cancer antigen (MCA) in patients with breast disease: comparison with CEA.
Boccardo F; Bombardieri E; Zanardi S; Valenti G; Zanaboni F; Valtolina M; Seregni E; Crippa F
Int J Biol Markers; 1991; 6(1):12-20. PubMed ID: 1856512
[TBL] [Abstract][Full Text] [Related]
12. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
[TBL] [Abstract][Full Text] [Related]
13. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
14. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W
Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
[TBL] [Abstract][Full Text] [Related]
15. Serial tumour markers serum carcinoembryonic antigen and cancer antigen 15-3 assays in detecting symptomatic metastasis in breast cancer patients.
Bahrami A; Mortazavizadeh MR; Yazdi MF; Chamani M
East Mediterr Health J; 2012 Oct; 18(10):1055-9. PubMed ID: 23301361
[TBL] [Abstract][Full Text] [Related]
16. Clinical value of a mucin-like carcinoma-associated antigen in monitoring breast cancer patients in comparison with CA 15-3.
Miserez AR; Günes I; Müller-Brand J; Walther E; Fridrich R; Mäcke H
Eur J Cancer; 1991; 27(2):126-31. PubMed ID: 1827273
[TBL] [Abstract][Full Text] [Related]
17. Circulating CA 549 and other associated antigens in breast cancer patients.
Pavesi F; Lotzniker M; Scarabelli M; Mauro E; Visconti G; Nicolato E; Moratti R
Oncology; 1994; 51(1):18-21. PubMed ID: 8265097
[TBL] [Abstract][Full Text] [Related]
18. Study of serum tumor markers CEA, CA 15.3 and CA 27.29 as diagnostic parameters in patients with breast carcinoma.
Rodríguez de Paterna L; Arnaiz F; Estenoz J; Ortuño B; Lanzós E
Int J Biol Markers; 1995; 10(1):24-9. PubMed ID: 7629423
[TBL] [Abstract][Full Text] [Related]
19. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M
Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
[TBL] [Abstract][Full Text] [Related]
20. Relationship between preoperative serum CA 15-3 and CEA levels and clinicopathological parameters in breast cancer.
Moazzezy N; Farahany TZ; Oloomi M; Bouzari S
Asian Pac J Cancer Prev; 2014; 15(4):1685-8. PubMed ID: 24641390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]